Limits...
Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test.

Iijima K, Ichikawa T, Okada S, Ogawa M, Koike T, Ohara S, Shimosegawa T - Dig. Dis. Sci. (2008)

Bottom Line: In this study, employing the EGT, we evaluated the effect of rebamipide, a cytoprotective anti-ulcer drug, on gastric mucus secretion.Total gastric mucin output was significantly increased by 53% by rebamipide administration from 3.2 +/- 1.2 mg hexose/10 min to 4.9 +/- 2.2 mg hexose/10 min (P < 0.01).Applying EGT, this study demonstrated that rebamipide administration increased gastric mucus secretion in human.

View Article: PubMed Central - PubMed

Affiliation: Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aobaku, Sendai, Miyagi, 980-8574, Japan. jiijima@int3.med.tohoku.ac.jp

ABSTRACT
We have previously developed a rapid, simple endoscopic method for evaluating gastrin-stimulated maximal acid output (the endoscopic gastrin test, EGT). In EGT, gastric fluid newly secreted over 10 min after gastrin stimulation is collected under direct endoscopic visualization. In this study, employing the EGT, we evaluated the effect of rebamipide, a cytoprotective anti-ulcer drug, on gastric mucus secretion. In ten Helicobacter pylori-negative healthy volunteers, gastric juice was collected by EGT prior to and after 4-week administration of rebamipide. The collected gastric juice was subjected to analysis for gastric mucus output. Total gastric mucin output was significantly increased by 53% by rebamipide administration from 3.2 +/- 1.2 mg hexose/10 min to 4.9 +/- 2.2 mg hexose/10 min (P < 0.01). Further analysis by ion-exchange chromatography revealed that rebamipide administration induced a specific increase in acidic mucin rich in sialic acid. Applying EGT, this study demonstrated that rebamipide administration increased gastric mucus secretion in human.

Show MeSH
Changes in volume of gastric aspirates collected with the endoscopic gastrin test (EGT). Gastric aspirates were collected by EGT prior to and after 4-week rebamipide administration (a), or at a 4-week interval without any treatment (b). There were no significant differences between the two occasions in either group. NS, not significant
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2690849&req=5

Fig1: Changes in volume of gastric aspirates collected with the endoscopic gastrin test (EGT). Gastric aspirates were collected by EGT prior to and after 4-week rebamipide administration (a), or at a 4-week interval without any treatment (b). There were no significant differences between the two occasions in either group. NS, not significant

Mentions: The volume of secreted gastric fluid was not significantly different between prior to and after 4-week administration of rebamipide (prior to: 35.4 ± 8.1 ml versus after: 33.0 ± 7.3 ml) (Table 1; Fig. 1). Regarding the effects of rebamipide on gastric acid secretion, the administration did not significantly alter gastric acidity (prior to: 107.4 ± 27.2 mEq/l versus after: 120.0 ± 15.9 mEq/l) nor total gastric acid output (prior to: 3.8 ± 1.2 mEq/10 min versus after: 4.0 ± 1.3 mEq/10 min).Fig. 1


Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test.

Iijima K, Ichikawa T, Okada S, Ogawa M, Koike T, Ohara S, Shimosegawa T - Dig. Dis. Sci. (2008)

Changes in volume of gastric aspirates collected with the endoscopic gastrin test (EGT). Gastric aspirates were collected by EGT prior to and after 4-week rebamipide administration (a), or at a 4-week interval without any treatment (b). There were no significant differences between the two occasions in either group. NS, not significant
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2690849&req=5

Fig1: Changes in volume of gastric aspirates collected with the endoscopic gastrin test (EGT). Gastric aspirates were collected by EGT prior to and after 4-week rebamipide administration (a), or at a 4-week interval without any treatment (b). There were no significant differences between the two occasions in either group. NS, not significant
Mentions: The volume of secreted gastric fluid was not significantly different between prior to and after 4-week administration of rebamipide (prior to: 35.4 ± 8.1 ml versus after: 33.0 ± 7.3 ml) (Table 1; Fig. 1). Regarding the effects of rebamipide on gastric acid secretion, the administration did not significantly alter gastric acidity (prior to: 107.4 ± 27.2 mEq/l versus after: 120.0 ± 15.9 mEq/l) nor total gastric acid output (prior to: 3.8 ± 1.2 mEq/10 min versus after: 4.0 ± 1.3 mEq/10 min).Fig. 1

Bottom Line: In this study, employing the EGT, we evaluated the effect of rebamipide, a cytoprotective anti-ulcer drug, on gastric mucus secretion.Total gastric mucin output was significantly increased by 53% by rebamipide administration from 3.2 +/- 1.2 mg hexose/10 min to 4.9 +/- 2.2 mg hexose/10 min (P < 0.01).Applying EGT, this study demonstrated that rebamipide administration increased gastric mucus secretion in human.

View Article: PubMed Central - PubMed

Affiliation: Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aobaku, Sendai, Miyagi, 980-8574, Japan. jiijima@int3.med.tohoku.ac.jp

ABSTRACT
We have previously developed a rapid, simple endoscopic method for evaluating gastrin-stimulated maximal acid output (the endoscopic gastrin test, EGT). In EGT, gastric fluid newly secreted over 10 min after gastrin stimulation is collected under direct endoscopic visualization. In this study, employing the EGT, we evaluated the effect of rebamipide, a cytoprotective anti-ulcer drug, on gastric mucus secretion. In ten Helicobacter pylori-negative healthy volunteers, gastric juice was collected by EGT prior to and after 4-week administration of rebamipide. The collected gastric juice was subjected to analysis for gastric mucus output. Total gastric mucin output was significantly increased by 53% by rebamipide administration from 3.2 +/- 1.2 mg hexose/10 min to 4.9 +/- 2.2 mg hexose/10 min (P < 0.01). Further analysis by ion-exchange chromatography revealed that rebamipide administration induced a specific increase in acidic mucin rich in sialic acid. Applying EGT, this study demonstrated that rebamipide administration increased gastric mucus secretion in human.

Show MeSH